Update on COVID‐19 vaccination in pediatric solid organ transplant recipients. (20th January 2022)

• Record Type: Journal Article
• Authors: Dulek, Daniel E.; Ardura, Monica I.; Green, Michael; Michaels, Marian G.; Chaudhuri, Abanti; Vasquez, Luciola; Danziger‐Isakov, Lara; Posfay‐Barbe, Klara M.; McCulloch, Mignon I.; L'Huillier, Arnaud G.; Benden, Christian
• Is Part Of: Pediatric transplantation. Volume 26:Number 5(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-01-20
• Subjects: children -- COVID‐19 -- immunization -- SARS‐CoV‐2 -- solid organ transplantation -- vaccination -- vaccine; Transplantation of organs, tissues, etc. in children -- Periodicals; 617.95408305
• DOI: 10.1111/petr.14235
• Languages: English
• ISSNs: 1397-3142

Abstract

Abstract: Background: COVID‐19 vaccination has been successful in decreasing rates of SARS‐CoV‐2 infection in areas with high vaccine uptake. Cases of breakthrough SARS‐CoV‐2 infection remain infrequent among immunocompetent vaccine recipients who are protected from severe COVID‐19. Robust data demonstrate the safety, immunogenicity, and effectiveness of several COVID‐19 vaccine formulations. Importantly, Pfizer‐BioNTech BNT162b2 mRNA COVID‐19 vaccine studies have now included children as young as 5 years of age with safety, immunogenicity, and effectiveness data publicly available. In the United States, emergency use authorization by the Federal Drug Administration and approval from the Centers for Disease Control/Advisory Committee on Immunization Practices have been provided for the 5‐ to 11‐year‐old age group. Methods: Members of the International Pediatric Transplant Association (IPTA) provide an updated review of current COVID‐19 vaccine data with focus on pediatric solid organ transplant (SOT)‐specific issues. Results: This review provides an overview of current COVID‐19 immunogenicity, safety, and efficacy data from key studies, with focus on data of importance to pediatric SOT recipients. Continued paucity of data in the setting of pediatric transplantation remains a challenge. Conclusions: Further studies of COVID‐19 vaccination in pediatric SOT recipients are needed to better understand post‐vaccine COVID‐19 T‐cell and antibody kinetics and determine the optimal vaccine schedule. Increased COVID‐19 vaccine acceptability, uptake, and worldwide availability are needed to limit the risk that COVID‐19 poses to pediatric solid organ transplant recipients.